secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262591
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint
--------------------------------------------------------------------------------

- ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).
- Net product revenue $370M (PMO $238.5M, ELEVIDYS $131.5M); total revenue $399.4M, down 15% YoY.
- GAAP net loss $179.9M ($1.80 per share) vs net income $33.6M ($0.34) in Q3 2024.
- Refinanced convertible debt to 2030; disposed Arrowhead equity; positive cash flow in Q3.
- ELEVIDYS labeling discussions with FDA nearing conclusion; non-ambulatory indication removal expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/0001193125-25-262591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312525262591/srpt-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer